The US neurological disorder drugs market is anticipated to grow significantly over the forecast period (2020-2026). Rising cases of neurological disorders, geriatric population, and rapid advancement by the key players operating in the neurological disorder drugs landscape are some of the key factors that drive the growth of the US neurological disorder drugs industry.
Besides, frequent developments in healthcare and drug discovery are leading to the introduction of new drugs for the treatment of neurological diseases. Key authorities such as WHO, National Institutes of Health, and National Institute of Neurological Disorders and Stroke are taking productive steps that flares-up the research activities for the novel drug discovery. For instance, in August 2019, the National Center for Advancing Translational Sciences and National Institute of Neurological Disorders and Stroke invited researchers to conduct a study on rare neurological and neuromuscular disorders.
Browse the full report description of "US Neurological Disorder Drugs Market Size, Share & Trends Analysis Report by Disorder Type (Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Huntington Disease, and Others), and Forecast 2020-2026" at https://www.omrglobal.com/industry-reports/us-neurological-disorder-drugs-market
Besides the presence of the key players such as Eli Lilly and Co., Merck & Co. Inc., and Pfizer Inc. are contributing to the growth of the US neurological disorder drugs market growth. Further, the well-established healthcare infrastructure and a significant rise in the population with the age group ranging between 18 and 64 are also driving the market growth. For instance, as per the US Census Bureau, the total population in the US was more than 325.7 million, of which 62% was constituted by 18-64 age group people.
Market Coverage
Key questions addressed by the report
o Recovery Timeline
o Deviation from the pre-COVID-19 forecast
o Most affected segment
US Neurological Disorder Drugs Market – Segmentation
By Disorder Type